Display options
Cite
Ng SP, Pollard C, Kamal M, et al. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019;3:22doi: 10.1038/s41698-019-0097-y.
Ng, S. P., Pollard, C., Kamal, M., Ayoub, Z., Garden, A. S., Bahig, H., Gunn, G. B., Frank, S. J., Skinner, H. D., Phan, J., Berends, J., Morrison, W. H., Johnson, J. M., Ferrarotto, R., Sturgis, E. M., Mohamed, A. S. R., Lai, S. Y., Fuller, C. D., & Rosenthal, D. I. (2019). Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ precision oncology, 322. https://doi.org/10.1038/s41698-019-0097-y
Ng, Sweet Ping, et al. "Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy." NPJ precision oncology vol. 3 (2019): 22. doi: https://doi.org/10.1038/s41698-019-0097-y
Ng SP, Pollard C, Kamal M, Ayoub Z, Garden AS, Bahig H, Gunn GB, Frank SJ, Skinner HD, Phan J, Berends J, Morrison WH, Johnson JM, Ferrarotto R, Sturgis EM, Mohamed ASR, Lai SY, Fuller CD, Rosenthal DI. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019 Sep 27;3:22. doi: 10.1038/s41698-019-0097-y. eCollection 2019. PMID: 31583278; PMCID: PMC6764977.
Copy Download .nbib Format: NLM
Share it on

NPJ Precis Oncol. 2019 Sep 27;3:22. doi: 10.1038/s41698-019-0097-y. eCollection 2019.

Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy.

NPJ precision oncology

Sweet Ping Ng, Courtney Pollard, Mona Kamal, Zeina Ayoub, Adam S Garden, Houda Bahig, G Brandon Gunn, Steven J Frank, Heath D Skinner, Jack Phan, Joel Berends, William H Morrison, Jason M Johnson, Renata Ferrarotto, Erich M Sturgis, Abdallah S R Mohamed, Stephen Y Lai, Clifton D Fuller, David I Rosenthal

Affiliations

  1. 1Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  2. 2Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria Australia.
  3. 3The University of Texas Health Science Center, San Antonio, TX USA.
  4. 4Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  5. 5Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  6. 6Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX USA.

PMID: 31583278 PMCID: PMC6764977 DOI: 10.1038/s41698-019-0097-y

Abstract

Second primary malignancy (SPM) may occur after index head and neck cancer (HNC) treatment. This study evaluated the prevalence and outcome of SPM in patients with HNC treated with definitive radiotherapy. Eligible patients include those with index mucosal HNC treated with definitive radiotherapy between 2000 and 2010. SPM was defined as an invasive cancer at a noncontiguous site diagnosed at least 6 months after completion of radiotherapy. Clinical data were collected, and the Kaplan-Meier method was used to estimate overall survival. In total, 1512 patients were studied. The majority of patients had index oropharyngeal cancer (86%). In all, 130 (9%) patients developed a SPM. The risk of SPM increased exponentially with time with 5-, 10-, and 15-year rates of 4, 10, and 25%. Half of SPMs were within the head and neck or thoracic regions. SPM rates were significantly higher (

© Crown 2019.

Keywords: Cancer epidemiology; Head and neck cancer

Conflict of interest statement

Competing interestsS.P.N. is funded by the Australian Postgraduate Award, RSNA Fellow Grant, and RANZCR research grants. Dr. C.D.F. is a Sabin Family Foundation Fellow. C.D.F. receives funding and sal

References

  1. Br J Cancer. 2013 Jul 9;109(1):1-7 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1195-203 - PubMed
  3. Laryngoscope. 2008 Aug;118(8):1350-6 - PubMed
  4. Lancet Oncol. 2011 Apr;12(4):353-60 - PubMed
  5. Head Neck. 1999 May;21(3):204-10 - PubMed
  6. J Clin Oncol. 2011 Feb 20;29(6):739-46 - PubMed
  7. Radiother Oncol. 2009 Apr;91(1):4-15; discussion 1-3 - PubMed
  8. Cancer. 1992 Jul 1;70(1):14-9 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):427-35 - PubMed
  10. Cancer. 1956 Nov-Dec;9(6):1248-52 - PubMed
  11. J Clin Oncol. 2008 Feb 1;26(4):612-9 - PubMed
  12. Otolaryngol Head Neck Surg. 1990 Jul;103(1):14-24 - PubMed
  13. Cancer. 1994 Oct 1;74(7):1933-8 - PubMed
  14. Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):449-56 - PubMed
  15. Cancer. 1977 Oct;40(4 Suppl):1872-8 - PubMed
  16. Ann Otol Rhinol Laryngol. 1995 Dec;104(12):946-54 - PubMed
  17. N Engl J Med. 2010 Jul 1;363(1):24-35 - PubMed
  18. Lancet Oncol. 2010 Aug;11(8):781-9 - PubMed
  19. Cancer. 2018 Jul 1;124(13):2785-2800 - PubMed
  20. Cancer. 2005 Jun 1;103(11):2326-33 - PubMed
  21. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7 - PubMed
  22. Oral Oncol. 2009 Sep;45(9):e85-9 - PubMed
  23. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8 - PubMed
  24. J Clin Oncol. 2013 Dec 20;31(36):4550-9 - PubMed
  25. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed

Publication Types

Grant support